Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma.
Dendritic cells (DCs) are potent antigen-presenting cells that play important roles in regulating immune responses in cancer. Immunotherapy using these immunocytes has become an accepted therapeutic modality. We previously reported that hyperthermia using magnetic nanoparticles induces antitumor immunity, which could be activated by adjuvant including cytokines. In the present study, we investigated the therapeutic effects of hyperthermia combined with DC immunotherapy on mouse EL4 T-lymphoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into an EL4 nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the surface of the tumor reached 45 degrees C and was maintained by controlling the magnetic field intensity. Hyperthermia treatment was repeated twice with 24 h intervals. After hyperthermia, immature DCs were directly injected into the EL4 nodule. As a result, complete regression of tumors in 75% (6/8) of the mice was observed, while the percentage of complete regression of tumors was 12.5% (1/8) in the case of mice treated by hyperthermia alone. This novel cancer therapy, which we have termed "heat immunotherapy", may be applicable to patients with advanced malignancies.
Tanaka
Kouji
K
Department of Biotechnology, School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.
Ito
Akira
A
Kobayashi
Takeshi
T
Kawamura
Tatsuyoshi
T
Shimada
Shinji
S
Matsumoto
Kazuhiko
K
Saida
Toshiaki
T
Honda
Hiroyuki
H
D000818:Animals; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000637:transplantation*; D006979:Hyperthermia, Induced / Q000379:methods*; D007167:Immunotherapy / Q000379:methods*; D008223:Lymphoma / Q000473:pathology* / Q000628:therapy*; D008280:Magnetics / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D043942:Nanotubes; D016896:Treatment Outcome